Klinikum Bremen-Mitte gGmbH
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
The research programme at Klinikum Bremen-Mitte gGmbH focuses on improving outcomes for children and adolescents with blood‑related cancers. Current studies evaluate novel combinations and conditioning strategies to boost event‑free survival in acute myeloid leukemia, myelodysplastic syndrome, and Down‑syndrome associated myeloid leukemia, while also addressing aggressive B‑cell lymphoma in pediatric patients.
- Event‑free survival trials for pediatric AML using targeted agents
- Comparison of treosulfan‑based versus busulfan‑based conditioning regimens
- Rituximab‑enhanced chemotherapy schedules for limited B‑cell lymphoma
- IDH‑mutant AML treatment with oral inhibitors combined with chemotherapy
- FLT3‑mutated AML therapy comparisons to refine maintenance approaches
With 14 investigators leading eight active trials, the centre integrates translational science and patient‑centered care to advance therapeutic options for hemic and lymphatic malignancies.
Neoplasms
The department’s oncology arm addresses solid tumours through collaborative, multinational studies. Research includes optimizing treatment intensity for Ewing sarcoma and exploring molecular determinants of response in HER2‑negative, hormone‑receptor‑positive breast cancer. By integrating advanced imaging and genomic profiling, investigators aim to refine therapeutic windows and identify resistance mechanisms.
- Maintenance therapy addition to standard regimens for Ewing sarcoma
- Radiation dose escalation versus de‑escalation for local disease control
- Spatial‑temporal analysis of ribociclib efficacy in advanced breast cancer
- Molecular pattern mapping to predict treatment resistance
- Pediatric solid‑tumor network trials improving trial accessibility
The site’s participation in international consortia strengthens its capacity to test innovative approaches that may reshape standard care for diverse neoplastic conditions.
Virus Diseases
In response to the global pandemic, the centre has launched several studies targeting SARS‑CoV‑2 infection. These trials assess the effectiveness of antiviral agents and immunomodulators in both moderate and severe COVID‑19 cases, with a particular focus on immunocompromised patients. The adaptive platform design enables rapid evaluation of emerging therapies while maintaining rigorous safety oversight.
- Therapeutic impact on disease progression in hospitalized moderate COVID‑19 patients
- Mortality reduction strategies for severe or critical COVID‑19
- Baricitinib added to standard of care versus placebo in immunocompromised cohorts
- Adaptive multicenter trial framework for emerging infectious diseases
- Safety and efficacy monitoring of novel COVID‑19 treatments
By contributing to a European pandemic research network, the site supports rapid generation of evidence that can inform clinical practice worldwide.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 6 therapeutic areas and 15 of 48 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 48 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1GPOH gGmbH4active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GPOH gGmbH4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Bremen-Mitte gGmbH
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS | Institut fuer Frauengesundheit GmbH | Phase III | Recruiting | Oct 2022 | — |
IMP list
lock Showing 1 of 48 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Etoposide | 5 | Unknown | 2017-07-12 | 2024-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.